Growing Incidence of Congestive Heart Failure Drives Global Dilated Cardiomyopathy Therapeutics Market09 Dec 2015
Dilated cardiomyopathy is a condition strongly related to heart attacks, in which the ventricles are enlarged, resulting in a thinning of cardiac walls, and insufficient pumping of blood. Dilated cardiomyopathy can occur at any age, though it is most common in the 20-40 demographic. One of the major reasons of dilated cardiomyopathy is genetic. Some other factors that can cause dilated cardiomyopathy are thyroid disorders, viral infections of the heart, diabetes, alcoholism, and heart valve malformations.
Angiotensin II Receptor Blockers Held Largest Share of Dilated Cardiomyopathy Therapeutics Market in 2013 by Revenue
The dilated cardiomyopathy therapeutics market worldwide is segregated on the basis of drug class, pipeline drugs, and geography. The dilated cardiomyopathy therapeutics market globally in terms of drug class is broadly classified as angiotensin-converting enzyme (ACE) inhibitors, beta blockers, aldosterone antagonists, and angiotensin II receptor blockers (ARBs). Of all the drug class, angiotensin II receptor blockers held the largest share of the dilated cardiomyopathy therapeutics market in 2013 by revenue, followed by beta blockers.
Request For Sample Report:- http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2293
The high demand for the leading drugs for the treatment of dilated cardiomyopathy from developed regions such as Europe and North America is a reason for the large market shares of these classes of drugs. When used in combination either with ACE or ARBs, aldesterone antagonist drugs have proven to have a positive impact on the reduction of progressive conditions such as Duchenne muscular dystrophy (DMD).
The global dilated cardiomyopathy therapeutics market was worth US$651.0 million in 2013. By 2020, the global dilated cardiomyopathy therapeutics market is projected to be worth US$328.6 million which shows a decline of 7% CAGR from 2014 to 2020.
Clinical Trials May Halt Expected Reduction of Dilated Cardiomyopathy Therapeutics Market
The dilated cardiomyopathy therapeutics market worldwide is driven by growing incidence of congestive heart failure which is significantly related with DCM. On a global scenario, dilated cardiomyopathy is associated to 30% to 40% for congestive heart failure cases every year. Due to the growing incidence of congestive heart failure worldwide, several companies have initiated clinical trials for the advancement of therapeutics for dilated cardiomyopathy.
Some of the clinical trials undertaken are a phase II study by Array BioPharma in 2015 for its drug class ARRY-371797, a phase II study by Celladon Corporation in 2014 for its drug class MYDICAR. The dilated cardiomyopathy therapeutics market is expected to get a boost on the successful completion of these clinical trials. However, implantable devices such as heart pumps, pacemakers, and advancement in gene therapy will restrain the growth of dilated cardiomyopathy therapeutics market.
North America Leads Global Dilated Cardiomyopathy Therapeutics Market
According to geographical segmentation, the dilated cardiomyopathy therapeutics market is divided into four regions, which are Asia Pacific, Europe, North America, and Rest of the World (RoW). North America held the largest share of the dilated cardiomyopathy therapeutics market in 2013 owing to rising cases of heart diseases and acceptance for branded drugs.
The U.S. and Canada make up the dilated cardiomyopathy therapeutics market in North America. The prevalence of DCM in the U.S. is high; 5-8 people out of every 100,000 are diagnosed with DCM. In Canada, heart failure accounts for 9% of total deaths in the country, which is driving the dilated cardiomyopathy therapeutics market in North America.
In Europe, countries such as Spain, Germany, the U.K., and Italy contribute significantly towards the growth of the dilated cardiomyopathy therapeutics market. The dilated cardiomyopathy therapeutics market is growing in Asia Pacific and Rest of the World (RoW) owing to rising economic power, higher incomes, and growing demand for generic drugs.
Some of the key players in the dilated cardiomyopathy therapeutics market are Teva Pharmaceutical Industries Ltd , Merck & Co., Inc., Array BioPharma, Inc., Celladon Corporation, GlaxoSmithKline plc, Pfizer, Inc., Janssen Pharmaceuticals, Inc., Novartis International AG, Sanofi S.A., AstraZeneca plc and Vericel Corporation.
Browse Full Report With TOC:- http://www.transparencymarketresearch.com/dilated-cardiomyopathy-market.html
Transparency Market Research (TMR) is a next-generation provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
Transparency Market Research
90 State Street,
Albany NY - 12207